Fig. 1: Study overview.

Overview of clinical features (WHO grade 2−4, primary vs recurrent tumour—top row; gender and age distribution—second row) stratified by tumour subtype. Left column (green) depicts oligodendroglioma (n = 58), middle column (blue) depicts astrocytoma (n = 89) and right column (red) depicts glioblastoma (n = 256). Schematic representation of tumour location for each glioma subtype by lobe (frontal, temporal, parietal, occipital, insula, other location) in the third row. Survival is shown as overall survival and progression free survival classified by tumour grade for oligodendroglioma and astrocytoma (overall survival—coloured solid line, progression free survival—black dashed line). Overall survival and progression free survival for glioblastoma is shown by MGMT methylation status (methylated—coloured solid line, unmethylated—coloured dashed line, unknown—black line). Kaplan-Meier curves are plotted with significance between groupings estimated using the log-rank test. P-values are two-sided and unadjusted. Last row demonstrates molecular markers stratified by tumour subtype (wild type—pink, mutant—green, unknown—grey).